In addition, we received great support from Inova Diagnostics Corporate representatives: Patricia Swartwood – Marketing VP, Kaz Nakanishi – Marketing Director and Silvia Casas – Clinical Science Manager.
Regarding Aptiva, after introducing the novel PMAT (Particle based Multi Analyte) technology, we discussed in detail all the novel analytes that will be launched on the new platform. The analysis of those autoantibodies will help laboratorians and clinicians to close the “seronegative” gap in autoimmune disorders. The different autoantibodies profiling will help stratifying patients with autoimmune related conditions.
The focus group continued with the comparison of Aptiva platform versus our major competitors (Bio-Rad and Phadia) and with a brief discussion on reimbursement strategy related to novel biomarkers.
We opened the Marketing Meeting on Wednesday, with a presentation of the 2018 commercial data, as well as the strategy for 2019; we focused on novel parameters now available on BIO-FLASH®, in particular on QUANTA Flash® Calprotectin benefits and strengths. We listened to a success story regarding the successful implementation of Calprotectin test in Poland and Czech Republic. Session continued with another success story: the first Integrated Lab in Norway. Information related to instruments from competition were also provided. We closed the meeting with updates on the Integrated Lab and we showed some of our collaborations and studies, currently ongoing in several hospitals, to strengthen the value of our biomarkers on both BIO-FLASH and Aptiva.
Thank you to all the participants for their contribution!
Autoimmunity Team